Loading clinical trials...
Loading clinical trials...
A Phase 1/2 Open Label Study of LabVax 3(22)-23 and Adjuvant GM-CSF Alone or in Combination With Pembrolizumab in Subjects With Labyrinthin-Positive Adenocarcinomas
Conditions
Interventions
Antineoplastic Vaccine
Sargramostim
+1 more
Locations
1
United States
University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
Start Date
October 13, 2021
Primary Completion Date
January 1, 2026
Completion Date
January 1, 2030
Last Updated
May 21, 2024
NCT05969860
NCT04879121
NCT05053971
NCT03907475
NCT06311214
NCT04704661
Lead Sponsor
Tianhong Li
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions